Avenue Therapeutics CFO Joseph Vazzano resigns; CEO Lucy Lu appointed interim CFO

AVENUE THERAPEUTICS, INC.

Joseph Vazzano resigns as CFO effective Jan 14, 2022, to pursue other opportunities; no disagreement with company.
Vazzano will transition to a consulting role under a consulting agreement dated Jan 7, 2022.
Board appoints Dr. Lucy Lu, current President and CEO, as interim CFO and Principal Financial Officer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Vazzano

Chief Financial Officer

ATXI · AVENUE THERAPEUTICS, INC.

Effective: 2022-01-14
Successor: Lucy Lu
Filed: January 7, 2022, 6:59 PM ET

Mr. Joseph Vazzano notified Avenue Therapeutics, Inc. (the “Company”) that he was resigning from his role as the Company’s Chief Financial Officer, effective January 14, 2022, to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Vazzano departed as Chief Financial Officer at AVENUE THERAPEUTICS, INC..

Action: resigning
Role: Chief Financial Officer

Exact text from the filing

Mr. Joseph Vazzano notified Avenue Therapeutics, Inc. (the “Company”) that he was resigning from his role as the Company’s Chief Financial Officer, effective January 14, 2022, to pursue other opportunities.

View on SEC.gov

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-002269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.